Mitumomab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | GD3 ganglioside |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Mitumomab (BEC-2) is a
The first phase III clinical trial began in 1998.[2][3] In 2005 and again in 2008, results were published showing no benefit to patients receiving mitumomab and BCG.[4][5]
See also
- Anti-ganglioside antibodies
References
- ^ "Mitumomab - AdisInsight". Adisinsight.springer.com. 2005-06-13. Retrieved 2017-01-06.
- ^ Clinical trial number NCT00037713 for "Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG" at ClinicalTrials.gov
- ^ Clinical trial number NCT00006352 for "Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer" at ClinicalTrials.gov
- PMID 18676140.
- PMID 16192577.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |